首页> 美国卫生研究院文献>Acute Medicine Surgery >A summary of the Japan septic disseminated intravascular coagulation study
【2h】

A summary of the Japan septic disseminated intravascular coagulation study

机译:日本化脓性弥散性血管内凝血研究综述

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Over the past few decades, the large, international, randomized controlled trials of anticoagulant therapies for patients with sepsis have not yielded any improvement in mortality rates. However, in Japan, anticoagulant therapies are administered for sepsis patients with disseminated intravascular coagulation (DIC), but not for sepsis patients without DIC. Furthermore, epidemiological data regarding sepsis in Japan are scarce. Therefore, a nationwide multicenter retrospective observational study, the Japan Septic Disseminated Intravascular Coagulation (JSEPTIC DIC) study, was undertaken. The JSEPTIC DIC study enrolled 42 intensive care units and included 3,195 patients with sepsis. The results of the JSEPTIC DIC study indicated the following: (i) anticoagulant therapy may be effective in sepsis‐induced DIC patients at high risk for death, (ii) recombinant human soluble thrombomodulin administration and antithrombin supplementation are associated with survival benefits in patients with sepsis‐induced DIC.
机译:在过去的几十年中,针对脓毒症患者进行抗凝治疗的大型国际随机对照试验并未使死亡率得到任何改善。但是,在日本,对具有弥散性血管内凝血(DIC)的脓毒症患者进行抗凝治疗,而对没有DIC的脓毒症患者不给予抗凝治疗。此外,关于日本败血症的流行病学数据很少。因此,进行了一项全国性的多中心回顾性观察性研究,即日本败血症性弥散性血管内凝血研究(JSEPTIC DIC)。 JSEPTIC DIC研究招募了42个重症监护病房,包括3,195名败血症患者。 JSEPTIC DIC研究的结果表明:(i)抗凝治疗可能对败血症诱发的DIC高死亡风险患者有效;(ii)重组人可溶性凝血调节蛋白的给药和抗凝血酶的补充与罹患糖尿病的患者的生存获益相关败血症诱导的DIC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号